Global Pericardium Diseases and Drugs Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Pericardium Diseases and Drugs Market was valued at $4.2 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 5.4% CAGR, to an estimated market size of $5.4 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global pericardium diseases and drugs market encompasses the pharmaceutical treatments and therapeutic interventions used to manage inflammation of the pericardium, the thin sac surrounding the heart. The scope includes NSAIDs, colchicine, corticosteroids, and emerging biologic therapies (such as IL-1 inhibitors) for acute, chronic, and recurrent pericarditis, while excluding general cardiac surgeries not specific to pericardial drainage or resection.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Pericardium Diseases and Drugs Market in the period 2025-30:
- The rapid adoption of biologic therapies, specifically IL-1 inhibitors like rilonacept, is transforming the treatment landscape for refractory and recurrent cases.
- Increasing global prevalence of cardiovascular diseases and autoimmune disorders is driving the baseline demand for pericarditis management.
- Advancements in diagnostic imaging, such as cardiac MRI and CT, are enabling earlier and more accurate identification of pericardial inflammation.
- A significant shift toward dual therapy protocols, combining colchicine with traditional NSAIDs, is becoming the standard of care to reduce recurrence rates.
- The aging global population is expanding the high-risk patient pool, as elderly individuals are more susceptible to post-cardiac injury syndromes.
- Growing clinical focus on recurrent pericarditis as a distinct unmet medical need is accelerating R&D investment and orphan drug designations.
- The transition toward personalized medicine is allowing clinicians to tailor anti-inflammatory dosages based on individual patient biomarkers and response history.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- NSAIDs
- Colchicine
- Corticosteroids
- Biologics & Targeted Therapies